The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N- hydroxylated compounds. Upon reconstitution with cytochrome b5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared ...
